Compare Anheuser-Busch Inbev SA (BUD) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Sana Biotechnology Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.31 (market cap $159.01B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Anheuser-Busch Inbev SA is far larger — about 140.7× Sana Biotechnology Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.67% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| BUD | SANA | |
|---|---|---|
Market Cap | $159.01B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $5.92 |
52-Week Low | $57.93 | $2.68 |
Enterprise Value | $223.42B | $1.05B |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.20, down 4.69% today, with technical indicators showing bearish momentum. The stock shows solid fundamentals with 2025 revenue of $59.32B and net income margin improving to 11.52%. Recent Q2 2026 earnings beat expectations with EPS of $1.21 versus $1.09 estimate. Analyst consensus remains bullish with 57.8% buy ratings and $90.17 price target, representing 14% upside potential from current levels.
The outlook remains positive given strong cash flow generation and debt reduction trends, though near-term technical weakness and competitive pressures in the beer industry present risks. Institutional activity shows mixed signals with recent share sales by Cetera Investment Advisers offset by Bank of New York Mellon purchases.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
